All In Biotech

Drug Trial Radar · NCT05027802

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy.

Last checked: Nov 20, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

61

Actual

Start

Mar 14, 2022

Primary completion

Nov 30, 2024

Study completion Nov 30, 2024

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Aug 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.

Conditions

  • Fibrodysplasia Ossificans Progressiva (FOP)

Interventions

  • PalovaroteneDrug

    Palovarotene will be taken orally once daily at approximately the same time each day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious Treatment-related Treatment-emergent Adverse EventsTime frame: From signing the informed consent form (Day 1) up to 30 days post last dose, approximately 32 months

Locations

13 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California San Francisco (UCSF)

    San Francisco, California

  • Mayo Clinic

    Rochester, Minnesota

  • Children's Hospital of Philidelphia

    Philadelphia, Pennsylvania

  • The Perelman School of Medicine - The University of Pennsylvania

    Philadelphia, Pennsylvania

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Hospital Israelita Albert Einstein

    Morumbi, São Paulo, Brazil

  • Toronto General Hospital

    Toronto, Canada

  • Groupe Hospitalier Necker Enfants Malades

    Paris, France

  • Istituto Giannina Gaslini

    Genoa, Italy

  • Hospital Universitario Ramon y Cajal

    Colmenar Viejo, Spain

  • Norrlands Universitetssjukhus

    Umeå, Sweden

  • Royal National Orthopaedic Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.